Ocugen Provides Business Update with Second Quarter 2025 Financial Results
1. OCGN commenced dosing in OCU410ST Phase 2/3 trial for Stargardt disease. 2. OCU400 Phase 3 trial on track for a 2026 BLA filing. 3. Signed exclusive rights to OCU400 in Korea with up to $11 million payments. 4. OCGN reports $27.3 million cash, providing runway into Q1 2026. 5. Leadership changes and strategic partnerships aim to boost gene therapy advancements.